𝔖 Bobbio Scriptorium
✦   LIBER   ✦

PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease

✍ Scribed by Gary Landreth; Qingguang Jiang; Shweta Mandrekar; Michael Heneka

Publisher
Springer-Verlag
Year
2008
Tongue
English
Weight
241 KB
Volume
5
Category
Article
ISSN
1933-7213

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Xanomeline: A selective muscarinic agoni
Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease
✍ Frank P. Bymaster; Celia A. Whitesitt; Harlan E. Shannon; Neil DeLapp; John S. W 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 3 views

Xanomeline is a novel muscarinic receptor agonist relatively devoid of parasympathomimetic side effects. Xanomeline had high affinity for muscarinic receptors and much lower affinity for a variety of other neuronal receptors in radioligand binding assays. Functional studies in cell lines transfected

Development of CDD-0102 as a selective M
Development of CDD-0102 as a selective M1 agonist for the treatment of Alzheimer's disease
✍ William S. Messer Jr.; Kenneth A. Bachmann; Colleen Dockery; Afif A. El-Assadi; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 1 views

## Abstract Selective muscarinic agonists might be useful in the treatment of Alzheimer's disease. To help characterize the activity and functional selectivity of two M~1~ muscarinic agonists, secretion of amyloid precursor protein, brain penetration, side effect profiles, cognition‐enhancing prope